Scholarlink

Background <p>This study aims to identify the genetic and clinical characteristics that affect the glycemic and weight loss responses to vildagliptin (Vilda) plus metformin (Met) among Egyptian obese type 2 diabetic (T2DM) patients. Furthermore, these responses were linked to homocysteine (Hcy) level as another cardiovascular risk factor.</p> Methods <p>One hundred twenty-six obese newly diagnosed T2DM Egyptian patients (38.9% male and 61.1% female<b>)</b> fulfilling the inclusion criteria and signing the consent form were treated with Met plus Vilda for 12&#xa0;months and genotyped for rs6741949 in the <i>DPP4</i>, rs6923761 in the <i>GLP1R</i>, and rs2285676 in the <i>KATP (KCNJ11)</i> genes. At 12&#xa0;months post-treatment, the glycemic and weight loss-responses were defined as a reduction of the baseline HbA1c by more than 1% and a reduction of the baseline weight by more than 3% respectively.</p> Results <p>The GG genotype of the <i>DPP4</i>, <i>GLP1R</i>, and <i>KATP</i> had the significant highest distribution and glycemic response to Vilda/Met than other genotypes [odds ratio (OR) = 3.55, 8.56 &amp; 4.89; 95% confidence interval (CI) 1.13–9.51, 1.32–92.4 &amp; 1.2–22.2; <i>p</i> = 0.033, 0.021 &amp; 0.03, respectively]. However, the AA genotype of rs6923761 in the <i>GLP1R</i> had a significantly higher weight loss response than GA and GG genotypes (OR = 0.39 &amp; 0.17; 95% CI 0.65–0.44 &amp; 0.22–0.67, <i>p</i> = 0.84). Further analysis showed that lower baseline weight and BMI were associated with better glycemic and weight loss responses to Vilda/Met, while gender had no effect. Of note, glycemic and body weight loss responders show a higher reduction in Hcy level than non-responders.</p> Conclusions <p>Glycemic control and body weight loss, and hence amelioration of Hcy level by Vilda as add-on therapy to Met in Egyptian T2DM obese patients are subjected to genetic variation in one or more of the <i>DPP-4</i>, <i>GLP1R</i> and <i>KATP</i> genes involved in Vilda's modes of action. The GG genotype for the three genes is associated with better glycemic response; however, the AA genotype of <i>GLP1R</i> is associated with better weight loss response. Gender has no effect; however, lower initialbody weight results in better glycemic and weight loss response.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Genetic variants associated with glycemic and weight loss response to vildagliptin as add-on therapy to metformin in Egyptian obese type 2 diabetic patients: potential consequences on cardiac risk factors

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月21日

查看全文
  • Khalid Saber,
  • Raed Ismail,
  • Atef Bassyouni,
  • Mohamed El-shafee,
  • Memy H. Hassan

摘要

Background

This study aims to identify the genetic and clinical characteristics that affect the glycemic and weight loss responses to vildagliptin (Vilda) plus metformin (Met) among Egyptian obese type 2 diabetic (T2DM) patients. Furthermore, these responses were linked to homocysteine (Hcy) level as another cardiovascular risk factor.

Methods

One hundred twenty-six obese newly diagnosed T2DM Egyptian patients (38.9% male and 61.1% female) fulfilling the inclusion criteria and signing the consent form were treated with Met plus Vilda for 12 months and genotyped for rs6741949 in the DPP4, rs6923761 in the GLP1R, and rs2285676 in the KATP (KCNJ11) genes. At 12 months post-treatment, the glycemic and weight loss-responses were defined as a reduction of the baseline HbA1c by more than 1% and a reduction of the baseline weight by more than 3% respectively.

Results

The GG genotype of the DPP4, GLP1R, and KATP had the significant highest distribution and glycemic response to Vilda/Met than other genotypes [odds ratio (OR) = 3.55, 8.56 & 4.89; 95% confidence interval (CI) 1.13–9.51, 1.32–92.4 & 1.2–22.2; p = 0.033, 0.021 & 0.03, respectively]. However, the AA genotype of rs6923761 in the GLP1R had a significantly higher weight loss response than GA and GG genotypes (OR = 0.39 & 0.17; 95% CI 0.65–0.44 & 0.22–0.67, p = 0.84). Further analysis showed that lower baseline weight and BMI were associated with better glycemic and weight loss responses to Vilda/Met, while gender had no effect. Of note, glycemic and body weight loss responders show a higher reduction in Hcy level than non-responders.

Conclusions

Glycemic control and body weight loss, and hence amelioration of Hcy level by Vilda as add-on therapy to Met in Egyptian T2DM obese patients are subjected to genetic variation in one or more of the DPP-4, GLP1R and KATP genes involved in Vilda's modes of action. The GG genotype for the three genes is associated with better glycemic response; however, the AA genotype of GLP1R is associated with better weight loss response. Gender has no effect; however, lower initialbody weight results in better glycemic and weight loss response.